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Abstract
Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer’s disease (AD) and, as such, have 
become the focus of therapeutic development. Recent research, however, shows that these proteins have been highly con-
served throughout evolution and may have crucial, physiological roles. Such functions may be lost during AD progression 
or be unintentionally disrupted by tau- or Aβ-targeting therapies. Tau has been revealed to be more than a simple stabiliser 
of microtubules, reported to play a role in a range of biological processes including myelination, glucose metabolism, axonal 
transport, microtubule dynamics, iron homeostasis, neurogenesis, motor function, learning and memory, neuronal excitabil-
ity, and DNA protection. Aβ is similarly multifunctional, and is proposed to regulate learning and memory, angiogenesis, 
neurogenesis, repair leaks in the blood–brain barrier, promote recovery from injury, and act as an antimicrobial peptide and 
tumour suppressor. This review will discuss potential physiological roles of tau and Aβ, highlighting how changes to these 
functions may contribute to pathology, as well as the implications for therapeutic development. We propose that a balanced 
consideration of both the physiological and pathological roles of tau and Aβ will be essential for the design of safe and 
effective therapeutics.
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Introduction
Alzheimer’s disease (AD) is a terminal neurodegenera-
tive disorder associated with severe progressive dementia 
[155]. The disease is characterised by key neuropathological 
hallmarks of chronic inflammation, synapse loss, neuronal 
death and the diagnostic accumulation of insoluble protein 
aggregates, intracellular neurofibrillary tangles (NFTs), and 
extracellular amyloid plaques [28, 155, 258]. The disease 
begins as a primary disorder of short-term memory, learn-
ing, and spatial navigation, due to early degeneration of the 
temporal lobe [174]. In the end stages, however, the spread 
of pathology throughout the brain results in multimodal 
deficits, including loss of verbal and motor control [174]. 
Unfortunately, AD is a common disorder, affecting over 50 
million individuals worldwide and representing 60–80% of 
all dementia cases [5]. Whilst there is evidence that demen-
tia incidence may be declining in the population, potentially 
attributable to better management of modifiable risk factors, 
it is not yet known whether this trend will counteract the 
impact of a shift towards an ageing population [57, 229]. 
As the population ages, and the risk of developing dementia 
increases, AD cases are currently set to triple by the year 
2050, representing a tremendous global, socio-economic 
challenge [5]. As existing treatments only target symptoms 
and do not slow (let alone halt or reverse) the progression of 
the disease, the need to develop a disease-modifying thera-
peutic has never been more urgent [155].
Since the identification of microtubule-associated pro-
tein tau (MAPT) and amyloid beta (Aβ) as the components 
of NFTs and extracellular plaques, respectively, research 
has primarily focused on the toxic roles these proteins play 
in AD pathogenesis [136, 171, 241]. Accumulation of Aβ 
causes synapse damage [106, 132, 274] and can induce 
cognitive and electrophysiological deficits [270]. Similarly, 
whilst tau was discovered as a microtubule-associated pro-
tein (MAP) [276], attention has been drawn to the toxic 
effects of tau hyperphosphorylation and aggregation [9]. As 
such, therapeutic development has focused heavily on tar-
geting these proteins through preventing their aggregation, 
inhibiting their production, or promoting their clearance 
[155]. Despite promising results in pre-clinical studies, no 
clinical trials have produced meaningful benefits for patients, 
with trials being halted due to adverse side effects such as 
liver toxicity, encephalitis, vasogenic oedema, and even 
exacerbation of cognitive decline [203, 286]. It is becoming 
increasingly apparent that the involvement of “pathologi-
cal” proteins in AD is complex and nuanced [241]. There is 
mounting evidence that these proteins may serve a number 
of crucial physiological functions that could be disrupted in 
the development of AD pathology or by Aβ- or tau-lowering 
therapeutics.
In this review, we discuss the emerging evidence for key 
physiological roles of tau and Aβ. The toxic roles of these 
proteins have been extensively reviewed elsewhere [94, 155, 
241], and thus, we aim to highlight possible loss of function 
phenotypes in disease, as well as identify potentially detri-
mental side effects of tau- (Table 1) or Aβ (Table 2)-lower-
ing therapeutics if not appropriately targeted. This will be 
especially important when considering treatment of the adult 
nervous system, where the lack of developmental compensa-
tion may reveal phenotypes masked in constitutive knock-
outs. We propose that balancing the consideration of both 
physiological and pathological roles of tau and Aβ will be 
essential for the design of safe and effective AD therapeutics.
The origin of Aβ and tau
Aβ biogenesis
Amyloid precursor protein (APP) is encoded by the APP 
gene on chromosome 21 [84, 125, 257]. Aβ is produced 
by the sequential cleavage of APP by beta-site amyloid 
precursor protein cleaving enzyme 1 (BACE1) [265] and 
γ-secretase [55], which have recently been shown to form 
a multiprotease complex to maximise cleavage efficiency 
[151] (Fig. 1a). BACE1 cleaves APP at Asp1 or Glu11 of the 
Aβ sequence [265], after which the catalytic component of 
γ-secretase (presenilin) sequentially trims the resulting car-
boxy-terminal fragment at ε-, ζ-, and γ-cleavage sites, releas-
ing the Aβ intracellular domain (AICD) and Aβ (between 37 
and 49 amino acids in length) [292]. Mutations in presenilin, 
or environmental factors, consistently decrease the proces-
sivity of γ-secretase, resulting in fewer cuts per APP mol-
ecule and consequentially the release of longer Aβ peptides 
[42]. This amyloidogenic (or β) cleavage of APP is in direct 
competition with an alternative α-cleavage pathway, where 
α-secretase bisects APP in the middle of the putative Aβ 
protein, thus preventing Aβ production [70]. Under physi-
ological conditions, Aβ1-40 (~ 90% of total Aβ) and Aβ1-42 
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(~ 5–10% of total Aβ) are the most abundant isoforms in 
humans [184]. Aβ1-40 is produced exclusively within the 
trans-Golgi network (TGN) and then packaged into secretory 
vesicles, whilst Aβ1-42 can be made in either the TGN or the 
endoplasmic reticulum [91]. Aβ monomers readily assemble 
to form higher order structures, from low-molecular-weight 
oligomers, to protofibrils and eventually to fibrils contain-
ing β-sheets (Fig. 1b), with longer isoforms of Aβ showing 
the greatest propensity to oligomerise and aggregate [34]. 
Increased production of Aβ1-42, at the expense of Aβ1-40 
generation, is a common feature of both familial [42] and 
sporadic AD [101], with the increased aggregation of this 
peptide believed to be responsible for driving neurotoxicity 
[34].
Tau production
Tau is encoded by the MAPT (microtubule-associated pro-
tein tau) gene on chromosome 17 [189], which generates a 
total of 6 tau protein isoforms through alternative splicing 
of exons 2, 3, and 10 in the central nervous system (CNS) 
[94] (Fig. 2a). Inclusion of exon 10 produces tau with 4 
microtubule-binding domains (4R), whilst omission of exon 
10 excludes microtubule-binding domain R2 (3R). Similarly, 
tau can include (2 N or 1 N) or exclude (0 N) amino-terminal 
inserts through regulation of exons 2 and 3. In the periph-
eral nervous system (PNS), exons 4A, 6, and 8 can also be 
transcribed, resulting in the production of larger tau pro-
teins [75]. Tau expression is developmentally regulated, with 
only 0N3R tau being expressed in the foetal brain, whilst 
all isoforms are expressed in adult humans [94]. However, 
adult mice and rats show almost exclusive expression of 4R 
tau [94]. In humans, there are two principle genetic haplo-
types at the MAPT locus; H1, which is directly orientated 
(~ 75% of the Caucasian population), and H2, which has 
an inverted sequence (~ 25% of the Caucasian population) 
[269]. Interestingly, the H2 haplotype appears to be almost 
exclusively Caucasian in origin, with Central Asian popula-
tions having H2 allele frequencies of ~ 5% and African, East 
Asian, and Native American populations effectively lacking 
H2 expression [71]. Possession of the H1 versus H2 haplo-
type subtly alters the tau isoform expression profile [269]. 
Tau can undergo a vast array of post-translational modifica-
tions including phosphorylation, acetylation, ubiquitination, 
sumoylation, methylation, glycation, glycosylation, polyami-
nation, nitration, isomerisation, and oxidation (reviewed in 
[94]). Tau monomers can aggregate to form oligomers and 
higher order fibrils (Fig. 2b). However, whilst Aβ can largely 
self-assemble, tau phosphorylation is believed to be impor-
tant for its aggregation [9].
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Aβ and tau are expressed throughout the body
Tau and the key proteins required to produce Aβ [APP, 
BACE1, and components of γ-secretase (presenilin-1)] 
are expressed in a variety of tissues throughout the body 
(as reported by The Human Protein Atlas [262] (Fig. 3)). 
Whilst tau is predominantly found in brain and peripheral 
nerves, tau protein expression has been detected in diverse 
locations including salivary glands, breast tissue, cardiac 
myocytes, skeletal muscle, the pancreas, and kidneys [296]. 
Similarly, in addition to the brain, the key components of 
the Aβ-processing pathway [APP, BACE1, and presenilin-1 
(PS1)] are co-expressed in the pancreas, appendix, gastroin-
testinal tract, and both male and female reproductive organs 
[297–299]. It is likely, therefore, that both Aβ and tau will 
serve functions beyond the CNS.
Aβ and tau are evolutionarily conserved
Both tau and Aβ show remarkable evolutionary conser-
vation. An Aβ-like sequence has been reported in sea Ta
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Fig. 1  a The two pathways through which APP can be cleaved. The 
non-amyloidogenic (α) pathway (left-hand side of diagram) involves 
the cleavage of APP by α-secretase, within the Aβ sequence, to 
form C-terminal fragment α (CTFα) and soluble APP α (sAPPα). 
γ-secretase then cleaves the resulting CTFα, releasing the Aβ intra-
cellular domain (AICD) and the extracellular p3 fragment. The amy-
loidogenic (β) pathway (right-hand side of the diagram) involves the 
cleavage of APP by BACE1 to form CTFβ and sAPPβ. γ-secretase 
then cleaves the resulting CTFβ, releasing the AICD and Aβ. b Aβ 
monomers can assemble to form higher order structures, from oli-
gomers, to protofibrils and eventually mature fibrils containing 
β-sheets which form the core component of amyloid plaques. Created 
with https ://biore nder.com/
 Acta Neuropathologica
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anemones, demonstrating that such peptides have been in 
existence from 540 to 630 million years ago [259]. The 
human Aβ sequence is over 95% homologous to that in other 
mammals, and over 90% in birds, reptiles, and amphibians 
[259]. Similarly, evidence of a MAPT-like gene has been 
found in lampreys, hagfish, and sharks, pinpointing an origin 
over 550 million years ago [247]. Such evolutionary conser-
vation raises the possibility that these proteins are involved 
in key biological functions. Identifying these functions will 
provide a greater understanding of the pathogenesis of AD, 
as well as informing how Aβ- or tau-targeting treatments 
could impact physiology.
Regulation of microtubules: the primary 
physiological role of tau?
Tau binds to and regulates the structure 
of microtubules
Since the discovery of tau in 1975 [276], a plethora of 
research has focused on the role of tau at microtubules 
(reviewed in [10]). Microtubule deficits are common in AD 
and related disorders, with studies reporting axonal transport 
deficits [1], and defective microtubule assembly [115]. Tau 
binds tubulin via its microtubule-binding domains [141], 
with a single tau molecule crosslinking multiple tubulin 
dimers [6]. Original studies found that tau stabilises micro-
tubules [62], reducing the frequency of catastrophes (sudden 
microtubule disintegration) [208]. Early studies found that 
tau reduces the concentration of tubulin required for poly-
merisation [276]. A mechanism for this process has recently 
been proposed, where conditions of macro-molecular crowd-
ing induce tau to form liquid-like drops [102]. Tubulin parti-
tions into these drops, effectively raising its concentration to 
drive nucleation of microtubule formation [102]. Crucially, 
tau from AD post-mortem brain tissue fails to stimulate 
microtubule formation [115] and hyperphosphorylation of 
tau [115, 192], mutations within microtubule-binding sites 
[83], or C-terminal truncation [192], all greatly reduce tau’s 
microtubule-binding capacity. These findings have con-
tributed to the established dogma that disease-associated 
hyperphosphorylation of tau promotes its dissociation from 
microtubules, reducing microtubule stability [9]. Whilst 
pseudo-phosphorylation of tau results in a fivefold decrease 
in the association rate of binding to microtubules, this sur-
prisingly does not impact tau’s dissociation rate, raising the 
question of whether tau hyperphosphorylation occurs prior 
to, or following, microtubule detachment in disease [192]. 
In support of the latter hypothesis, inducing microtubule 
catastrophe via stathmin application results in unphospho-
rylated tau falling off the microtubule and subsequently 
being phosphorylated in the cytoplasm [181]. Thus, the role 
of microtubule-associated tau appears to be more complex 
than originally thought, with recent studies demonstrating 
its diverse, subtle, and sometimes contradictory functions.
Beyond microtubule stability: tau as a regulator 
of microtubule dynamics
Tau is preferentially expressed within the axon and there 
is agreement that tau concentration increases towards the 
distal, labile end [213]. As such, a role for regulating micro-
tubule dynamics has been proposed. Indeed, tau knockdown 
in primary neurons results in a substantial drop in the labile 
microtubule mass with a corresponding increase in the stable 
domain [213]. Tau knockdown reduces neuronal outgrowth 
[150], impairs the repulsive response of the growth cone [22, 
147], disrupts axonal extension [36], delays neuronal matu-
ration [37, 54], and reduces microtubule density [96]. Tau 
also recruits end-binding proteins (EBs) to the stable micro-
tubule bundle, preventing them from tracking to microtubule 
ends where they increase catastrophe frequency [217]. How-
ever, not all tau depletion studies report deficits in microtu-
bule dynamics [261], with compensatory increases in other 
Fig. 2  a Tau is encoded by the MAPT gene on chromosome 17. A 
total of 6 tau protein isoforms are generated via alternative splicing of 
exons 2, 3, and 10. Inclusion of exon 10 produces tau with 4 micro-
tubule-binding (MTB) domains (4R), with omission of exon 10 pro-
ducing tau with 3 MTB domains (3R). Tau can include (2 N or 1 N) 
or exclude (0 N) amino-terminal inserts through regulation of exons 
2 and 3. Only 0N3R tau is expressed in the foetal human or mouse 
brain, with all 6 tau isoforms being expressed in adult humans. Adult 
mice and rats show almost exclusive expression of 4R tau. b Phos-
phorylated tau monomers can assemble to form oligomers, filaments 
(both straight and paired helical) and eventually tangles. N N-termi-
nus, PRD proline-rich domain, MTB microtubule-binding domains, C 
C-terminus. Created with https ://biore nder.com/
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MAPs potentially masking relevant functions [164, 266]. 
Indeed, MAPT and MAP1B double knockouts have a high 
mortality rate, showing a synergistic disruption to growth 
cone dynamics, axonal elongation, and neuronal migration, 
resulting in defective axonal tract and neuronal layer for-
mation [252]. Interestingly, an individual with frontotem-
poral dementia (FTD) was found to have a partial deletion 
of the MAPT gene, resulting in the production of truncated 
tau lacking the first microtubule-binding repeat [224]. This 
truncated tau exhibited dramatic reduction in microtubule-
binding capability, but acquired the ability to sequester 
MAP1B, potentially mediating both loss-of-function and 
gain-of-function disruption to microtubule dynamics, simi-
lar to double knockout mice [224].
Tau regulates axonal transport
Many studies have sought to determine whether tau regulates 
axonal transport. Knockdown of 4R tau in human induced 
pluripotent stem cell (iPSC)-derived neurons increases the 
velocity of mitochondrial transport [15]. Additionally, young 
P301L knockin mice, which exhibit reduced tau-microtubule 
binding, show enhanced anterograde transport [1, 83]. It is 
hypothesised that tau may compete with motor proteins for 
tubulin-binding sites, and overexpression of tau has been 
reported to cause “traffic jams” [242] and induce kinesin dis-
sociation from microtubules [61, 65, 233, 255]. Tau fibrils 
or oligomers can also inhibit axonal transport [124] and 
MAPT−/− neurons are resistant to Aβ-induced axonal trans-
port deficits [268]. Recent work has demonstrated a poten-
tial mechanism for this under physiological conditions, with 
two studies describing “island” regions of concentrated tau 
protein along the axon [233, 255]. Upon reaching the island 
boundaries, kinesin-1 motor proteins dissociate instantane-
ously from the microtubules, whilst dynein slowly moves 
through [233, 255]. Such differential regulation of motor 
proteins could allow tau to regulate axonal transport and 
cargo delivery, processes that may be disrupted in disease. 
However, other studies report that neither tau knockout nor 
overexpression alters axonal transport dynamics [288]. A 
“kiss-and-hop” binding of tau to tubulin has been proposed 
as a mechanism, whereby tau remains associated with micro-
tubules without clogging motor protein binding sites [118].
Tau protects microtubules from cleavage
An emerging role of tau is protecting microtubules from the 
microtubule-severing protein katanin [214, 233, 255, 287]. 
Recently described “tau islands” block katanin-tubulin bind-
ing, preventing breakdown of the microtubule lattice at these 
sites [233, 255]. Indeed, tau knockdown [214], or expression 
of pseudo-hyperphosphorylated tau [245], results in kata-
nin-mediated cleavage, loss of microtubules, and reduced 
axon length in vitro. Tau depletion also increases neuronal 
Fig. 3  Tissue-level protein expression of APP [297], BACE1 [298], and presenilin-1 [299] (indicating potential for Aβ production) and tau 
(MAPT) [296] according to the Human Protein Atlas [262]. Created with https ://biore nder.com/
 Acta Neuropathologica
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branching [287], raising the hypothesis that the preferential 
expression of tau in the axon may maintain a non-branched 
structure, in contrast to highly branched dendrites, which 
show low tau expression [287]. Pathological tau mislocalisa-
tion may, therefore, render axonal microtubules vulnerable 
to inappropriate cleavage [233]. Interestingly, Aβ-induced 
tau mis-sorting permits recruitment of tubulin tyrosine 
ligase-like 6 (TTLL6) to dendritic microtubules, promot-
ing spastin-mediated cleavage [289]. Tau location, there-
fore, appears vital for regulating its physiological versus 
pathological functions. Indeed, dendritic mis-sorting of 
tau also promotes aberrant clustering of Fyn, a key step in 
Aβ-mediated synaptotoxicity and spine collapse [116].
The future of therapeutics targeting microtubule 
(dys)function
Whilst microtubule-stabilising drugs, such as Taxol and 
Epothilone D, showed pre-clinical promise, replication of 
this success in humans is not yet forthcoming [286]. Forty 
five years of exploration of tau at the microtubule has trans-
formed understanding from tau being a simple “stabiliser”, 
to reveal a diverse array of physiological and pathological 
functions [10]. With development of tau-targeting therapies 
becoming increasingly common, careful maintenance of 
physiological tau at the axon, whilst also preventing mis-
sorting and pathological aggregation, will likely be crucial 
for therapeutic success. Interestingly, a recent study reported 
that Aβ-mediated dendritic simplification requires microtu-
bule stabilisation by unphosphorylated dendritic tau [85]. 
This finding raises concerns that reducing tau phosphoryla-
tion, a common goal of tau-targeting treatments, may nega-
tively impact neuronal connectivity in some circumstances, 
highlighting the complexity of untangling physiological 
from pathological modifications. Therefore, focus on other 
physiological functions of tau or Aβ may reveal more prom-
ising therapeutic targets.
Physiological roles at the synapse
Synapse loss is the strongest pathological correlate of cog-
nitive decline in AD [56, 258], so protecting these vital 
structures is a key therapeutic goal. Tau and Aβ are prime 
suspects for causing synaptic damage, with toxic species 
reported to accumulate at synapses [132, 250], disrupt key 
synaptic machinery [293], induce spine collapse [274], and 
target synapses for microglia-mediated pruning [52, 106]. 
Whilst toxic tau and Aβ are undoubtedly involved in AD 
pathology, there is growing evidence that these proteins 
play key physiological roles at the synapse that could be 
lost, or hijacked, to contribute to disease. Potential loss-of-
function at the synapse should be carefully considered when 
designing tau- or Aβ-targeting therapeutics to avoid exacer-
bating, or introducing new, synaptic pathology.
Physiological concentrations of Aβ enhance LTP
Studies of synapse function often use long-term poten-
tiation (LTP), an indicator of synapse strengthening, and 
long-term depression (LTD), an indicator of synaptic 
weakening, as electrophysiological correlates of learn-
ing and memory [14]. Pathological concentrations of 
Aβ applied to hippocampal slices disrupt LTP [270], but 
physiological concentrations may, in fact, be required for 
this process [210] (Fig. 4). A biphasic, or hormetic, role of 
soluble Aβ in regulating LTP has been proposed, whereby 
low (picomolar) concentrations of Aβ enhance LTP, whilst 
high (nanomolar) concentrations suppress LTP [92, 99, 
185, 210, 211]. Such experiments highlight a potential 
role for endogenous Aβ in regulating memory formation. 
Indeed, the extracellular concentration of Aβ increases 
after neuronal stimulation [123, 253] and interstitial fluid 
Aβ concentration positively correlates with neuronal activ-
ity in human brain [29]. Interestingly, both APP knockout 
[53] and BACE1 knockout [139, 154, 272, 273] in vivo 
induce cognitive deficits and impair LTP. Wild-type mice 
given BACE1 inhibitors also show a dose-dependent sup-
pression of LTP and impaired cognitive performance [74]. 
Treatment of wild-type slices with the anti-Aβ antibody 
Fig. 4  Schematic representation of the hormetic responses to tau and 
Aß concentration. There is an optimal concentration of tau or Aβ 
for a number of physiological functions. Too little protein (or loss 
of function modifications) or too much protein (or gain of function 
modifications) can both disrupt normal function. Effectively rescuing 
loss  of  function or preventing gain  of  function to maintain optimal 
physiological conditions should be the ultimate goal of therapeutics. 
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4G8 prevents LTP formation [185, 210] with LTP restored 
by application of picomolar oligomeric Aβ1-42 [210]. 
In vivo, hippocampal infusion of 4G8 [81, 185, 210] or 
siRNA to APP [185, 210] abolishes short-term memory 
in contextual fear conditioning [81, 185, 210] or the Mor-
ris Water Maze (MWM) [210]. Infusion of picomolar Aβ 
rescues this effect [81, 210], whilst Aβ-infusion into naive 
mice enhances reference and contextual fear memory [81, 
210, 211]. A potential hormetic role of Aβ raises the possi-
bility that physiological, learning-mediated Aβ production 
throughout life could eventually result in accumulation of 
Aβ to a toxic level, especially if clearance mechanisms 
fail. Indeed, in humans, brain regions in the default mode 
network that show high levels of neuronal activity in 
young adults closely correlate with regions most heavily 
burdened by amyloid in AD later in life [32].
Tau in LTP, LTD, and memory
Like Aβ, tau expression and secretion also increases 
following neuronal activity [131, 207], and studies in 
MAPT−/− mice have sought to explore the role of tau in 
synaptic function. Phenotypes of MAPT−/− mice vary, 
with findings differing depending on the model used, 
genetic background [146], cleanliness of the animal unit 
[186], diet [164], and the age of the animals when stud-
ied. Some studies do not report cognitive or synaptic defi-
cits in MAPT−/− mice [113, 146, 186, 254], and reports 
that there is compensatory upregulation of other MAPs 
highlight that developmental compensation could mask 
relevant effects [164]. Ma et al. found that 8-month old 
MAPT−/− mice had no cognitive deficits, but displayed 
significant MAP1A upregulation. At 19 months old, how-
ever, compensatory MAP levels fell, and extensive syn-
apse loss and cognitive deficits became apparent [164]. 
A recent study showed that acute tau knockdown in adult 
mice using viral shRNA resulted in reduced spine density, 
loss of synaptic proteins, and significant spatial memory 
impairments in the absence of compensatory MAP upregu-
lation [266]. Despite potential compensatory confounds, 
different groups have reported age-dependent cognitive 
deficits in MAPT−/− mice in contextual fear conditioning 
[3], Y-maze [146], MWM [164], and reversal learning 
tests [218]. Whilst one study found a severe LTP deficit 
in tau knockouts [3], LTD deficits are more commonly 
reported [128, 218]. Tau’s role in LTD appears to depend 
on its phosphorylation at serine 396 permitting AMPA 
receptor internalisation [218]. Crucially, a number of 
studies have reported human genetic cases of FTD [199, 
294] or intellectual disability [172, 232, 263] in which tau 
levels are drastically reduced compared to age-matched 
controls. Reduced soluble tau has also been reported in 
normal ageing [187], Parkinson’s disease (PD) [145], and 
AD [137, 191] (potentially due to sequestration of tau into 
NFTs). Together, this raises the possibility that loss of nor-
mal tau function may be partly responsible for cognitive 
and synaptic deficits in disease. Tau-targeting therapeutics 
should, therefore, be carefully managed to avoid disrupting 
physiological tau at the synapse.
Regulating neuronal hyperexcitability: could tau 
and Aβ act at opposite ends of the spectrum?
A common feature of many neurodegenerative and neu-
rodevelopmental disorders is the prevalence of seizures. 
Up to 22% of individuals with AD experience at least one 
seizure [178], whilst epilepsy is diagnosed in around 20% 
of individuals with autism spectrum disorder (ASD) [18]. 
Tau appears to be important for permitting seizure activ-
ity, and there is strong evidence that MAPT−/− mice [148], 
or mice treated with tau antisense oligonucleotides [59] 
are resistant to pentylenetetrazol-induced seizures. Cross-
ing MAPT−/− mice with genetic models of epilepsy [105], 
AD [219] and ASD [249] can rescue hyperexcitability and 
spontaneous epileptiform activity. As such, a role for tau in 
promoting or regulating neuronal excitability seems likely. 
It has recently been shown that hyperexcitation increases tau 
translation [131] and that tau translocation to the nucleus 
regulates the expression of the glutamatergic transporter 
protein, VGLUT1 [234]. Interestingly, MAPT−/− neurons 
lack extrasynaptic NMDA currents that, whilst their physi-
ological role is under debate, mediate excitotoxicity under a 
number of conditions [196]. Tau deficiency may also impact 
basal synaptic activity; one study reported that tau knockout 
neurons were hyperpolarised compared to wild-type cells 
[197], and a recent study found that tau knockout impaired 
basal neurotransmission in APP transgenic mice [209]. 
Lowering of tau levels could, therefore, be beneficial under 
conditions of hyperexcitability, but this must be carefully 
balanced against the risk of depressing normal neuronal 
activity.
When considering the impact of Aβ on neuronal excit-
ability, there are seemingly contradictory findings, poten-
tially explainable through the aforementioned hormetic role 
of Aβ (Fig. 4). Whilst low levels of Aβ can increase dendritic 
spine density [194], increase the number of docked vesicles 
[92], enhance glutamate release, promote excitotoxicity, and 
disrupt calcium homeostasis (particularly in early stages of 
disease) [7, 35, 225], Aβ production after synaptic activity 
could also act via negative feedback to prevent hyperactivity 
[123]. Indeed, Aβ can induce spine collapse and synapse loss 
[231, 274], increase the proportion of silent neurons [35], 
and disrupt neurotransmitter release via depletion of presyn-
aptic  PIP2 [99]. However, untangling the specific role of Aβ 
versus APP, alternative APP-processing products or BACE1 
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has proven difficult. Both APP−/− [243] and BACE1−/− [103, 
112, 130] mice fail to produce Aβ and show hypersensitiv-
ity to spontaneous and induced seizures. BACE1, however, 
cleaves a variety of proteins important for normal neuronal 
function, including seizure protein 6 [206]. Notably, con-
ditional BACE1 knockout in adult mice does not induce 
epileptiform activity [264], suggesting BACE1 or Aβ may 
play independent roles in the developing versus adult brain. 
To add further complexity, overexpression of APP, not Aβ, 
is responsible for hypersynchronous activity in some AD 
mouse models [26]. Therefore, clarification of the roles of 
Aβ, APP, and BACE1 will be essential to ensure balanced 
synaptic activity when therapeutically targeting amyloid 
dysregulation.
Neurogenesis, synaptogenesis, and structural 
plasticity
The formation of new neurons and synapses is an impor-
tant process both throughout development and in the adult 
nervous system. Early studies found that low concentrations 
of Aβ promote the survival of primary neurons [278] and 
have a neurogenic effect on neural progenitor cells [158]. 
Aβ1-42 also stimulates neurogenesis of subventricular zone 
precursors in vivo, raising the hypothesis that the early over-
stimulation of neurogenesis in AD may result in depletion 
of the stem cell pool and a decline in basal neurogenesis 
later in life [238]. Despite showing neurogenic properties, 
Aβ is often considered an antagonist to the formation of 
new synapses. Indeed, high concentrations of oligomeric 
Aβ can induce spine collapse [7, 231, 274], and synapse 
loss has been found to correlate with increased intraneuronal 
APP [295], plaque-proximal extracellular Aβ [132, 295], and 
accumulation of intraneuronal Aβ [97, 253]. However, long 
exposure to picomolar Aβ has also been found to increase 
the spine density in slice cultures [194]. Similarly, APP 
knockout in hippocampal neurons reduces neuronal branch-
ing and synapse formation [239], and APP−/− mice show a 
profound loss of synaptic proteins [53, 228], although loss 
of sAPPα (a non-amyloidogenic product of APP cleavage) 
may be a key contributor to this phenotype (reviewed in 
[47]). BACE1 has also been shown to play a role in nor-
mal synapse development, with BACE1−/− mice showing a 
developmental hearing impairment caused by aberrant syn-
aptic organisation in the cochlea [60]. Interestingly, adult 
wild-type mice treated with BACE1 inhibitors also show 
a reduction in dendritic spine density and formation [74], 
whilst BACE1 inhibitor treatment of APP/PS1 mice (which 
produce excess Aβ) slowed the rate of synapse loss around 
plaques [204]. Taken together, it once again seems likely 
that there is an optimal concentration of Aβ to maintain 
synapses, which must be considered when therapeutically 
targeting Aβ (Fig. 4).
Tau may also play a role in neuronal development and 
synaptogenesis. In vitro, stimulation of hippocampal neu-
rons with brain-derived neurotrophic factor (BDNF) nor-
mally increases tau expression and spine growth, but tau-
shRNA treatment significantly decreases baseline spine 
numbers and blocks the pro-synaptic response to BDNF 
[44]. In adult mice, tau-shRNA treatment reduced apical and 
basal dendrite density, supporting a role for tau in spine for-
mation or maintenance [266]. In MAPT−/− mice, new-born 
granule neurons in the dentate gyrus fail to migrate normally 
[78, 227], show reduced dendritic length, and have disrupted 
postsynaptic density (PSD) and mossy fiber terminal for-
mation [197]. Tau also mediates the pro-neurogenic effect 
of environmental enrichment on adult hippocampal neuro-
genesis and synaptic integration [197]. Other studies have 
reported impaired neurogenesis in MAPT−/− mice [107], 
potentially explaining the reduced brain weight reported 
in some strains [145, 146]. An anti-aggregant tau mouse 
model shows increased neurogenesis and hippocampal vol-
ume [120], whilst tauopathy models frequently show deficits 
in hippocampal neurogenesis [134], potentially highlight-
ing tau aggregation as a loss-of-function mechanism in this 
context. Tau knockdown also delays neuronal maturation in 
primary neurons [54] and induces transcriptional repression 
of neuronal genes [11], indicative of a potential role of tau in 
promoting neuronal differentiation. Some studies, however, 
contradict these findings, reporting increased neurogenesis 
in tau-deficient animals [50]. Further exploration of the role 
of tau in adult neurogenesis, and whether this translates to 
humans, is, therefore, required.
Regulating behaviour
Tau, hyperactivity, anxiety, and sleep
In addition to cognitive deficits, MAPT−/− mice show evi-
dence of hyperactivity, as measured by spontaneous loco-
motion in an open field test [23, 114], and substantially 
increased rearing behaviour [148]. MAPT−/− mice also spend 
significantly less time in the open arms of elevated Z-mazes 
and keep to the periphery of open field arenas, indicative of 
increased anxiety [86]. Tau may also help to regulate cir-
cadian behaviours, with MAPT−/− mice [41] or Drosophila 
[8], showing major abnormalities in the sleep–wake cycle, 
including increased wakefulness and disruption to nor-
mal circadian activities. Sleep disturbances are commonly 
reported in ageing and neurodegenerative disorders [281], 
so understanding how tau alterations impact sleep may be 
clinically relevant. Interestingly, tauopathy models often 
show disturbed sleep patterns [122] and hyperactivity [122, 
205] phenotypes, raising the possibility that tau mutations 
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could, for these behaviours, mimic the effect of tau depletion 
through loss of function.
Tau and the motor system
Another common feature of MAPT−/− mice is the appearance 
of FTD-P17-like motor dysfunction, suggesting that tau loss 
of function could be partly responsible for Parkinsonism in 
these individuals [145]. Notably, soluble tau levels in the 
substantia nigra of the brains of individuals with PD are 
44% lower than those observed in age-matched controls, 
indicating that loss of normal tau may contribute to motor 
deficits [145]. In mouse studies, a number of groups have 
reported significant impairment in balance beam or rotarod 
performance in tau knockouts [114, 145, 146, 157, 164, 
186], mice lacking 4R tau [93], and mice treated with tau-
shRNA [266]. Additionally, changes in gait [146], reduced 
locomotion [145, 146], and muscle weakness [114] have 
been recorded, and many MAPT−/− models also show loss of 
dopaminergic neurons [145, 146, 164]. Interestingly, treat-
ment of MAPT−/− mice with L-DOPA rescued motor pheno-
types in some models [145, 146], but another study reported 
a dopamine-independent motor deficit [186]. A recent study 
postulated that the age-dependent motor deficits observed 
in their MAPT−/− model were due to hypomyelination and 
degeneration of the sciatic nerve (discussed below), raising 
further questions about the effect of tau loss of function in 
the peripheral versus central nervous systems [157]. Inter-
estingly, motor deficits are common in tau-overexpressing 
transgenic mice [4, 77], and it has been reported that whilst 
modest overexpression of FTD-P17 mutant tau can improve 
motor performance in young animals, this progresses to 
severe paraparesis in later life [183]. In humans, the MAPT 
H1/H1 genotype is also associated with increased risk of 
neurodegenerative diseases affecting the motor system, 
such as corticobasal degeneration (CBD) and progressive 
supranuclear palsy (PSP) [108]. Taken together, it seems 
likely that, in addition to mutations potentially disrupting 
physiological roles of tau, changes in tau concentration may 
have a hormetic effect on motor function (Fig. 4). Whilst 
individuals with AD can develop motor symptoms [155], 
this is not considered the primary deficit, indicative that the 
location of tau changes within the brain (e.g., hippocampus 
versus substantia nigra or motor cortex) and peripheral nerv-
ous system is likely an important determinant of symptoms.
Regulation of myelination
Tau is important for normal myelination
Whilst many studies focus on neuronal damage, white matter 
hyperintensities (evidence of demyelination) are commonly 
reported in the early stages of AD and other tauopathies and 
correlate with tau burden [173]. A recent study describes 
human familial globular glial tauopathy, linked to MAPT 
mutations, that result in extensive tau deposits in oligoden-
drocytes [73]. Affected individuals show severe demyeli-
nation, defective myelin synthesis, and concomitant axonal 
damage [73]. Coiled bodies of tau in oligodendrocytes and 
demyelination are also common features of other primary 
tauopathies such as PSP and CBD [291]. Mouse models of 
tauopathy frequently demonstrate deficits in myelination, 
with evidence of filamentous tau inclusions developing in 
oligodendrocytes [149], resulting in defective myelination of 
the perforant path [117], spinal cord [149], and sciatic nerve 
[179]. Tauopathy-induced myelination deficits coincide 
with increased nerve conduction latency [117], cognitive 
decline [117], and motor impairments [179]. The mecha-
nism by which tau pathology leads to deficits in myelina-
tion has yet to be fully elucidated, but there is evidence that 
this could represent a loss of normal tau function. Tau is 
found within oligodendrocytes and Schwann cells under 
physiological conditions and is upregulated during devel-
opmental myelination [159]. siRNA-mediated knockdown 
of tau impairs oligodendrocyte process outgrowth, reduces 
myelin basic protein (MBP) expression, and impairs contact 
with axons in myelinating co-cultures [230]. Oligodendro-
cyte process outgrowth depends on the recruitment of tau 
and tubulin to activated Fyn-kinase rafts, with disruption 
of tau-microtubule binding reducing oligodendrocyte pro-
cess number and length [129]. Expression of an inducible, 
truncated tau (which retains the Fyn-binding domain but 
lacks microtubule-binding capability) in oligodendrocytes 
induced demyelination and gait abnormalities in mice [160]. 
MAPT−/− mice also show age-dependent degeneration of 
myelinated fibers, reduced nerve conduction, and progres-
sive hypomyelination [157, 237], resulting in motor [157] 
and nociceptive [237] impairments. Tau knockdown also 
restricts recovery after sciatic nerve damage, with mice 
showing defective myelin debris clearance and severely 
impaired Schwann cell migration and differentiation [285]. 
Similarly, MAPT−/− mice showed a worse clinical outcome 
after experimental autoimmune encephalomyelitis (EAE) 
(a model of demyelinating disease) [277]. Taken together, 
it seems likely that tau plays a key role in forming, main-
taining, and repairing myelin, potentially via the regulation 
of microtubule dynamics [129]. Tau hyperphosphorylation 
may disrupt this key function in disease, contributing to 
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the commonly observed white matter pathology. Whether 
myelination deficits will become a problem for tau-targeting 
therapeutics remains to be seen, but caution may be required 
to ensure normal oligodendrocyte and Schwann cell function 
is maintained.
Aβ and its cleavage enzymes may regulate 
myelination
A recent study reports that low concentrations of Aβ oligom-
ers can enhance oligodendrocyte survival in vitro [215]. Aβ 
peptides also induced translation of MBP, promoted oligo-
dendrocyte differentiation, and improved remyelination in 
demyelinated cerebellar slices [215]. BACE1−/− mice show 
delayed myelination and reduced myelin thickness in the 
PNS and CNS [110, 280], as well as impaired remyelina-
tion of peripheral nerves after injury [109, 111]. However, 
BACE1−/− phenotypes may be Aβ-independent, relying 
instead on the cleavage of neuregulins [109], highlighting 
a potential off-target effect of lowering Aβ through BACE1 
inhibition. Interestingly, BACE1, neuregulin-1, and Aβ 
expression increase during myelin repair following ischae-
mic stroke, suggesting a potential role in the myelin repair 
process [190]. However, oligomeric Aβ1-42 can also reduce 
oligodendrocyte number and induce motor deficits when 
injected intracerebroventricularly in mice [290]. Interest-
ingly, a recent study has found that the secreted metallopro-
tease ADAMTS4, located exclusively in oligodendrocytes 
in adult mice, is responsible for the production of highly 
amyloidogenic, N-truncated, Aβ4-x peptides [271]. Further 
studies will, therefore, be required to elucidate the role of Aβ 
peptides and their cleavage enzymes in oligodendrocytes, 
and to determine whether Aβ-targeting therapies will be ben-
eficial or detrimental in resolving white matter pathology in 
disease. Once again, it seems likely that a balance between 
preventing toxicity and maintaining physiological functions 
will be required.
Aβ regulates vasculature
Angiogenesis and Aβ: a question of balance?
There is mounting evidence that Aβ plays important roles 
in regulating vasculature. Studies in post-mortem human 
brains have found evidence for increased angiogenesis in 
AD [21, 58], with one study finding that vascular density in 
the hippocampus positively correlated with Aβ load [58]. 
Conversely, other studies have reported reduced vasculari-
sation in AD brains [76]. Studies in AD mice found evi-
dence for a dual-staged response to rising Aβ, with young 
animals showing increased vascular density compared to 
wild-type littermates, with reversal of the trend in old mice 
[21]. In vitro, Aβ can inhibit endothelial cell capillary for-
mation in a dose-dependent manner and stimulates capillary 
degeneration at high concentrations [201]. At low concentra-
tions, however, Aβ has been found to promote endothelial 
cell proliferation [27], induce formation of capillary-like 
structures [27], and increase vessel density in brain slice 
cultures [64]. In vivo studies using chick [27] or zebrafish 
embryos [40] and adult zebrafish retinas [51] find that Aβ 
peptides increase capillary density and induce formation of 
sprouting tip cells. BACE1−/− mice also show a significant 
reduction in retinal vascular density [38] and APP-deficient 
zebrafish, or zebrafish treated with a BACE1 inhibitor, 
have shorter hindbrain vessels with fewer cerebrovascular 
branches [163]. Crucially, application of human Aβ rescued 
the vascular phenotype in both APP-deficient and BACE1 
inhibitor-treated zebrafish [163], highlighting a primary role 
of endogenous Aβ in maintaining normal capillary density.
Whilst low levels of Aβ seem important for maintain-
ing physiological vascularisation, increasing levels of Aβ 
in early AD have been shown to promote pathological 
angiogenesis, resulting in excessive vascularisation and 
disturbance to normal blood flow [21, 58, 64]. Excessive 
cleavage of APP, or direct inhibitory action of Aβ, may over-
whelm or inhibit the activity of γ-secretase, thus reducing 
its availability to cleave Notch proteins, known angiogenesis 
inhibitors [27, 64]. Indeed, γ-secretase inhibitor treatment 
increases angiogenesis and vascularisation in a range of 
model systems [40]. Lowering Aβ levels, through immu-
nisation against Aβ [20] or BACE1 inhibition [64], restores 
normal vascular patterns in AD models. Indeed, a meta-anal-
ysis of clinical trials reports that people with AD receiving 
immunisations against Aβ1-42, show a significant reduction 
of endothelial cells and vascular density [20]. In another 
example of hormesis, either too little or too much Aβ may 
result in pathological alterations to capillary density (Fig. 4). 
Carefully controlling Aβ concentration will be important 
to restore and maintain physiological angiogenesis in AD.
Aβ as a “vascular plug”
Clinical trials targeting Aβ have unintentionally provided 
evidence for a further role of Aβ in the vascular system: 
repairing leaks in the blood–brain barrier (BBB) [30]. A 
side effect of a number of active or passive anti-Aβ immu-
notherapies has been the appearance of microhaemorrhages 
and brain oedema [203]. This pattern of pathology, vis-
ible by MRI, has been termed “Amyloid-Related Imaging 
Abnormalities” (ARIA) and has become synonymous with 
Aβ immunisation [240]. A meta-analysis of 14 Aβ-targeting 
clinical trials reported a fivefold increase in the incidence of 
ARIA in treated versus placebo AD groups, with many trials 
showing a dose-dependent effect and increased incidence 
in APOE4 carriers [203]. Aβ immunisation in AD mouse 
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models [24] and aged mouse lemurs [121] can also induce 
ARIA-like cerebral microbleeds.
At present, it is not fully understood why removal of 
Aβ causes haemorrhages. Deposition of amyloid in blood 
vessels [cerebral amyloid angiopathy (CAA)] is a common 
feature of AD [166]. One possibility is that sudden removal 
of amyloid from blood vessels could compromise vascu-
lar integrity, as amyloid may have completely replaced the 
vessel wall in some instances (grade 2 CAA) [166]. Alter-
natively, a number of groups have proposed a relationship 
between Aβ and blood clotting. Platelets are the primary 
source of Aβ within the blood [43] and Aβ can induce 
aggregation of platelets [69]. It has been postulated that Aβ 
could play a physiological role as a vascular sealant, which 
could become overactivated with age and disease [30]. The 
expression of APP and Aβ rises in response to haemorrhagic 
damage, such as induction of microhaemorrhages [80] and 
chronic hypertension [33]. APP−/− or BACE−/− mice also 
show increased mortality after ischaemic injury, with severe 
deficits in reactive blood flow compared to wild-type con-
trols [133]. Taken together, these findings add weight to the 
hypothesis that Aβ could serve a crucial role in vascular 
responses to injury, potentially explaining the appearance of 
ARIA after Aβ-immunotherapy. Conversely, high levels of 
Aβ can increase BBB permeability, potentially via reducing 
levels of tight junction proteins [127]. Interestingly, increas-
ing BBB permeability promoted clearance of Aβ from the 
brain and improved cognition in a mouse model of AD, 
indicative of a physiological negative feedback mechanism 
[127]. Once again, this demonstrates the delicate balance 
between Aβ acting to support physiological versus patho-
logical processes that must be considered to design safe, 
effective therapeutics.
Response to injury
Tau and Aβ increase after injury: a protective 
or pathological response?
Increasing evidence demonstrates that the levels of both 
tau and Aβ proteins increase following stroke [190], spi-
nal cord injury (SCI) [195, 212] and traumatic brain injury 
(TBI) [282]. TBI promotes tau aggregation and spreading 
[67], with levels of tau pathology detected via PET correlat-
ing with poor long-term neuropsychiatric outcomes [251]. 
Whilst increases in tau often correlate with poorer outcome 
after injury [251], increased soluble Aβ has been shown to 
correlate with improved neurological status in individuals 
with a TBI [29]. Similarly, the formation of Aβ deposits 
in demyelinating lesions in people with multiple sclerosis 
(MS) has been proposed as a potentially protective response 
to axonal injury [89]. This raises the question of whether 
increases in tau and Aβ after injury serve to promote recov-
ery, or whether they are involved in a detrimental pathologi-
cal cascade.
Aβ may promote recovery after brain injury
Attempts to clarify the function of increased Aβ after 
injury have produced conflicting results and it is often 
difficult to separate specific effects of Aβ from functions 
of APP, which is known to be upregulated in axons after 
injury and may have protective functions [100]. Whilst 
some groups found that BACE1 knockout or inhibition 
improves recovery after sciatic nerve injury [72] or TBI 
[153], others report that BACE1−/− mice have impaired 
remyelination after sciatic nerve lesion [109, 111] and 
worse functional outcome after SCI [195] or TBI [168]. 
Interestingly, both BACE1−/− and APP−/− mice have an 
increased risk of mortality following cerebral ischae-
mia, indicating that this is likely a consequence of Aβ 
loss [133]. Mannix et al. found that following controlled 
cortical impact (CCI), functional outcome is worse in 
BACE1−/− mice compared to wild-type mice [168]. A 
follow-up study demonstrated that motor function (but 
not spatial memory or histopathology) could be improved 
by administration of Aβ1-40 to BACE1−/− mice after CCI, 
demonstrating a potential role for Aβ in recovery [167]. 
In the same study, administration of Aβ to injured wild-
type animals worsened outcome, demonstrating a hormetic 
role for Aβ [167] (Fig. 4). Grant et al. also showed that 
peripheral administration of Aβ could reduce paralysis 
and demyelination in a mouse model of EAE, providing 
further evidence of a role for Aβ in promoting recovery 
after injury [89].
The effect of tau depends on the type of injury 
induced
Studies exploring the role of tau after injury have also 
been contradictory. MAPT−/− mice suffer worse functional 
outcome after sciatic nerve injury [285] and EAE [277], 
reminiscent of tau regulating physiological myelination 
(discussed earlier). Several studies, however, report that 
MAPT−/− mice are resistant to some functional and cogni-
tive deficits after TBI, although this depends on whether 
the injury was repetitive [45] and whether short-term 
or long-term outcomes were measured [256]. A study 
by Bi et  al. found that following experimental stroke, 
MAPT−/− mice were protected from neurological deficits 
and excitotoxic brain damage [19]. The authors suggested 
a mechanism for this effect whereby tau normally mediates 
excitotoxic Ras/ERK signalling by regulating SynGAP1 
postsynaptic compartmentalisation [19]. Whilst further 
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experiments are required in a range of injury models, it 
seems likely that the positive versus negative effects of 
targeting tau will depend largely on the type of damage 
induced and the normal recovery mechanisms required. 
An apparent role for tau in myelin repair may mean that 
individuals with AD who have a history of MS, for exam-
ple, could be at risk of worse outcome after receiving tau-
lowering therapies. Similarly, Aβ-lowering therapies may 
increase the risk of brain damage in individuals who go 
on to suffer a TBI, which may be a risk in individuals 
who frequently suffer falls [260]. Therefore, patient history 
could be key in assessing the risk for negative outcomes 
associated with comorbidities, prior to the administration 
of tau- or Aβ-targeting therapeutics.
Mitochondria and oxidative stress
Mitochondrial dysfunction is a key component of AD 
pathology
Mitochondrial dysfunction is an early and important patho-
genic feature of AD [98], and both tau and Aβ have been 
shown to separately and synergistically affect mitochondrial 
function [66]. Whilst most studies have examined the patho-
logical effects of tau and Aβ on mitochondria, there is some 
evidence that these proteins may also have physiological 
roles.
Aβ and tau deposition: cause of, or response to, 
oxidative damage?
Many studies have found an association between mitochon-
drial Aβ deposition and oxidative stress [66, 193]. However, 
the directionality of the observed events, i.e., whether Aβ 
accumulation is a cause of, or response to, oxidative stress, 
has proven difficult to ascertain. Somewhat counterintui-
tively, whilst oxidative stress is an early feature of AD, oxi-
dative damage decreases alongside increased Aβ deposition 
during AD progression [193]. Notably, neurons containing 
an NFT show a 40–56% decrease in oxidised nucleosides 
compared to non-tangle-bearing neurons [193], leading to 
the proposal that Aβ and tau may have antioxidant proper-
ties [235]. Interestingly, a gene called saitohin, located in 
the intron downstream of exon 9 within the MAPT gene, 
interacts with peroxiredoxin 6, an antioxidant enzyme that 
protects cells from oxidative damage [79]. Whilst further 
research is required to explore the interaction of saitohin 
with tau, it seems likely that gene-level changes to MAPT 
may also impact the function of saitohin. Therefore, cau-
tion may be required when utilising tau- or Aβ-targeting 
therapies, to avoid potential exacerbation of oxidative 
damage.
Tau as a regulator of mitochondrial mobility 
and health?
Tau has also been proposed to regulate mitochondrial 
function. Sapir et al. found that tau knockdown reduced 
mitochondrial mobility and increased the number of 
abnormal mitochondria [227]. A recent study reports that 
tau localises to the outer mitochondrial membrane under 
physiological conditions, proposing a role for tau in regu-
lating mitochondrial association, and calcium transfer, 
with the endoplasmic reticulum [48]. However, overex-
pression of tau can also impair mitochondrial transport 
[65] and mouse models of tauopathy demonstrate deficits 
in mitochondrial distribution [135]. These seemingly con-
tradictory results require further exploration and it seems 
likely that tau expression levels, post-translational modi-
fications, developmental stage, and potential compensa-
tion from other MAPs will all impact whether tau serves 
a physiological or pathological role at the mitochondria.
Aβ may function as an antimicrobial peptide
The antimicrobial protection/infection hypotheses 
of AD
In 2002, Robinson and Bishop proposed that Aβ is nor-
mally produced to “bind toxic solutes” with the formation 
of amyloid plaques being “an efficient means of presenting 
these toxins to phagocytes” [220]. Since then, a number of 
groups have built upon the idea of amyloidosis as an innate 
immune response and have proposed that increased Aβ 
deposition, caused by continuous activation of this path-
way through recurrent, chronic infection, may lead to the 
development of AD [182].
Aβ rises after infection and is associated 
with pathogens in the CNS
A number of studies have shown that infection with a 
range of pathogens, including Herpes simplex virus-1 
(HSV-1), Chlamydia pneumoniae and Borrelia burgdor-
feri, can increase production and deposition of Aβ in vitro 
and in vivo, where microbial DNA can be found associated 
with amyloid plaques (reviewed in [87]). Interestingly, a 
post-mortem study of individuals who had died from HIV/
AIDS found that over half of them possessed extensive 
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accumulation of Aβ in the brain, despite their young age 
(average age of death was 43 years old) [90]. Interestingly, 
treatment of HSV-1-infected cell cultures with the antiviral 
agent Acyclovir lowers intracellular Aβ accumulation and 
normalises BACE1 expression, leading to the proposal that 
antiviral therapies may be beneficial for the treatment of 
AD [162]. It is important to note, however, that human 
studies linking infections and AD are mostly correlational 
in nature. Whilst there is considerable evidence for a role 
of neuroinflammation in the progression of AD [106], it is 
possible that the increase in microbes in the AD brain is a 
response to rather than a cause of AD pathology. Break-
down of the BBB is common during neurodegenerative 
disease [248], and this could permit invasion of microbes 
circulating in the periphery, especially viruses, such as 
HSV, that are endemic in the population [283].
Aβ has antimicrobial activity
The increased expression of Aβ after infection is proposed 
to be an innate immune response, and there is evidence that 
Aβ can act as an antimicrobial peptide (AMP) (reviewed 
in [87]). Soscia et al. found that Aβ exhibits antimicrobial 
action of equal or greater potency than LL-37 (a human anti-
microbial peptide) against eight common microbes [236]. 
Application of Aβ also decreases the infectivity of HSV-1 
[162] in cell lines, and reduces the growth of Candida albi-
cans, Gram-negative, and Gram-positive bacteria [138, 
236] in culture. In vivo, Kumar et al. found that Aβ over-
expression significantly increases survival in 5xFAD mice 
infected with S. Typhimurium, and in C. elegans infected 
with C. albicans and S. Typhimurium [138]. The authors 
suggest that Aβ acts as an AMP by agglutinating and trap-
ping microbes via the binding of its heparin-binding domain 
to carbohydrates in microbe cell walls [138]. Alternatively, 
Aβ may form cation channels in cell membranes, inducing 
cell death via calcium dyshomeostasis [126]. Interestingly, 
APP−/− mice show a trend for increased mortality after 
infection [138] and a common side effect of Aβ-targeting 
therapies in clinical trials has been increased incidence of 
infections [87], although BBB disruption caused by removal 
of vascular amyloid could also explain this increased vulner-
ability [240].
Regulation of iron homeostasis
Iron homeostasis may be disrupted 
in neurodegenerative disorders
A number of groups have postulated that iron dyshomeo-
stasis could contribute to AD and other neurodegenerative 
diseases [140], with iron accumulation resulting in cellular 
oxidative damage, dysfunction, and death via ferroptosis, 
an iron-dependent form of regulated necrosis [140]. It 
remains unknown whether iron dyshomeostasis is a cause, 
or consequence, of neurodegenerative pathology, but there 
is evidence that tau and APP may play physiological roles 
in regulating cellular iron transport.
Tau and APP play a role in physiological iron 
transport
Whilst the role of Aβ in regulating iron homeostasis is 
unclear, APP has been proposed to have iron-export ferroxi-
dase activity and interacts with, and stabilises, a major iron 
transport protein, ferroportin [16, 63]. Indeed, APP−/− neu-
rons retain more iron [63] and APP−/− mice show vulnerabil-
ity to oxidative damage from dietary iron [63] and exhibit 
exaggerated age-dependent iron accumulation in the brain 
and liver [16]. Tau may also regulate iron transport, likely 
through mediating transport of APP to ferroportin [145]. Lei 
et al. found that MAPT−/− mice exhibit age-dependent iron 
accumulation associated with neurodegeneration, cognitive 
deficits, and parkinsonian-like motor deficits [145]. These 
deficits were rescued by treatment of aged MAPT−/− mice 
with the iron chelator clioquinol [144]. Interestingly, they 
also found that tau levels were reduced by ~ 40% in the sub-
stantia nigra of individuals with PD [145], and the authors 
hypothesise that loss of tau may contribute to the extensive 
iron accumulation reported in this brain region in PD. The 
same group reported that lithium-mediated reduction of tau 
in wild-type mice, or primary cortical neurons, results in 
iron accumulation in the brain and reduced cellular iron 
efflux [143]. Taken together, the effects of tau-lowering ther-
apeutics on iron homeostasis should be carefully considered 
when targeting tau in AD. As iron chelation has been shown 
to be beneficial in a MAPT−/− mouse model [144], poten-
tially detrimental side effects may be avoided by a combina-
torial approach targeting both tau and iron dyshomeostasis.
The role of tau and Aβ in the nucleus
Tau is located at the nucleus and interacts 
with oligonucleotides
Whilst the majority of tau protein is located in the cyto-
plasm, there is clear evidence for nuclear association of tau 
in cell lines [156, 165, 234], primary neurons [11], and in 
mouse [267] and human [68, 216] brain tissue. Nuclear tau is 
mostly unphosphorylated [246] and is often localised to the 
nucleolar border, co-localising with constitutive heterochro-
matin [169] and ribosomal DNA (rDNA) [226]. In vitro, tau 
readily binds RNA [31] and DNA [39, 275]. Tau binds the 
minor groove of DNA, in a manner analogous to histones, 
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via its proline-rich domain and microtubule-binding domain 
R2 [39, 275]. Tau’s ability to bind nucleic acids is disrupted 
by hyperphosphorylation [161], raising the possibility that 
such changes during disease may result in loss of function.
Tau protects DNA from damage
Neurons continuously face the harmful effects of oxidative 
stress and evidence points to a key role for tau in preventing 
DNA damage and promoting repair [267]. Cellular stress, 
induced by heat shock or reactive oxygen species (ROS), 
results in dephosphorylation of tau, translocation to the 
nucleus [246, 267] and increases the capacity for tau to 
bind DNA [246]. In vitro, tau protects DNA from thermal 
denaturation, DNAse digestion, and ROS-mediated damage 
[39, 275]. Hyperphosphorylation prevents tau from binding 
DNA, resulting in DNA breakage and deficient repair under 
experimental stress conditions [161]. Whilst primary neu-
ronal cultures from wild-type mice are resistant to hyperther-
mic conditions, DNA breaks caused by extensive heat shock 
become evident in tau-deficient neurons, damage which can 
be rescued by overexpression of human tau targeted to the 
nucleus [246]. In vivo, MAPT−/− mice show increased DNA 
fragmentation under physiological conditions and are highly 
susceptible to DNA breakage after hyperthermic stress 
[267]. MAPT−/− mice also show delayed repair of double-
strand breaks after heat shock which was especially evident 
in the CA1 hippocampal subfield [267]. Caution may, there-
fore, be required to ensure that tau-lowering therapies do not 
increase neuronal susceptibility to DNA damage.
Tau maintains chromosomal stability
Cells from individuals with MAPT mutations consistently 
show chromosomal aberrations, including breakages, gaps, 
aneuploidies, and translocations [222]. Interestingly, knock-
ing out one or both copies of tau in murine splenocytes 
resulted in a marked increase in aneuploidy, indicating that 
MAPT mutations could induce dysfunction via loss of func-
tion, potentially through disruption of the mitotic spindle 
[88]. In MAPT−/− neurons, hallmarks of normal pericentro-
meric heterochromatin (clustering of H3K9me3 and HP1α) 
are also disrupted [165, 169], indicating a role for tau in 
maintaining nucleolar integrity. Pericentromeric chromatin 
was also found to be disrupted in AD post-mortem brain 
tissue, further supporting a role for tau loss of function in 
disease [169].
Tau as a regulator of transcription
In addition to maintaining genomic integrity, tau may also 
regulate transcription of genes involved in neuronal function. 
A recent paper reported that shRNA knockdown of tau in 
neurons greatly reduced both mRNA and protein levels of 
VGLUT1 [234]. Overexpressing wild-type tau, or forcing tau 
translocation to the nucleus, resulted in increased VGLUT1 
transcription [234]. Remarkably, this effect was abolished 
when attempted with P301L-mutant tau, indicating a poten-
tial loss-of-function effect of this FTD-associated mutation. 
Tau has also been implicated in repressing transcription of a 
number of genes implicated in neuronal function [17], with 
tau depletion, resulting in upregulation of proteins such as 
BAF-57 (involved in neuron-specific gene repression) [11]. 
Additionally, tau knockdown alters rDNA transcription, 
although whether tau normally promotes [226] or represses 
[165] this process, and the implications for neuronal func-
tion, is still under debate. Overall, tau plays many roles at the 
nucleus and there is evidence for disruption of these func-
tions in disease. Preserving the physiological functions of 
tau at the nucleus may, therefore, provide therapeutic benefit 
in tauopathies.
Aβ at the nucleus ‑ a caution for tau‑lowering 
therapeutics?
Whilst the APP-processing product AICD is frequently asso-
ciated with the nucleus (reviewed in [47]), a nuclear role 
for Aβ has been less forthcoming. Exogenously applied, or 
transfected, Aβ can translocate to the nucleus in vitro and 
is found at the nucleus in adult wild-type or APP/PS1 mice 
[12]. Some studies have suggested that Aβ1-42 can regulate 
transcription, including upregulation of APP and insulin-
like growth factor receptors [12, 13]. However, most studies 
focus on the pathological roles of Aβ in the nucleus includ-
ing inducing DNA breaks [244] and increasing chromosome 
mis-segregation by disrupting physiological tau function 
[88]. The fact that Aβ induces DNA damage provides an 
interesting link between potential Aβ and tau pathology in 
disease. Perhaps, increasing Aβ-mediated DNA damage 
results in reactionary alterations to tau that become over-
whelmed in time. With this in mind, tau-lowering therapeu-
tics without additional targeting of Aβ may need to be care-
fully considered to prevent additional DNA damage resulting 
from the removal of physiological protection.
Aβ and tau may function as tumour 
suppressors
Do individuals with AD have reduced incidence 
of cancer?
An increasing number of studies have reported a striking 
inverse association between AD and many types of cancer 
(reviewed in [30]), with one study reporting that the risk 
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of developing cancer was 50% lower in individuals with 
AD [188]. This effect is not thought to be simply due to 
individuals with cancer dying earlier in life, as there is no 
such inverse correlation with other age-related disorders 
such as vascular dementia [221]. Of note, a recent paper by 
Rossi et al. showed that individuals with FTD possessing 
an MAPT mutation have an increased risk of developing 
cancer [223]. Together, such findings warrant exploration 
of whether tau and Aβ could function physiologically as 
tumour suppressors.
Aβ can act as a tumour suppressor
Aβ has been proposed to act as a tumour suppressor under 
a number of experimental conditions [30]. Studies demon-
strate that Aβ can suppress tumour growth [201] and inhibit 
cancer cell proliferation [202], with Aβ dimers/trimers being 
stronger tumour inhibitors than pentadecamers [202]. AD 
transgenic mice overexpressing Aβ also demonstrate reduced 
growth rate of implanted glioma tumours, with the authors 
proposing that high levels of Aβ could inhibit neoangiogene-
sis within the tumour mass [200]. Brothers et al. suggest that 
Aβ could also indirectly suppress tumour formation through 
intercepting oncogenic viruses, or via scavenging free metal 
ions, restricting availability of micronutrients required for 
cell proliferation [30]. It is worth noting that the majority 
of studies investigating Aβ as a potential tumour suppressor 
have used supraphysiological concentrations in their mod-
els. Therefore, it is difficult to discern whether Aβ has a 
role in tumour suppression at physiological concentrations 
in humans. A recent study found significantly decreased 
BACE1 expression in invasive ductal carcinoma, indicat-
ing that reduced levels of Aβ could potentially increase the 
proliferation rate of this aggressive tumour [284]. Counter-
intuitively, increased levels of APP have been found in a 
number of cancers, with worse outcomes associated with 
higher APP levels (reviewed in [198]). Further research is, 
therefore, required to elucidate the contribution of Aβ and its 
processing pathways to cancer pathogenesis and the poten-
tial impacts of Aβ-targeting therapies on cancer risk.
Loss of tau function may increase tumour incidence
As microtubules are crucial components of the mitotic spin-
dle and regulate the cell cycle [82], it seems plausible that 
tau could play a role in tumourigenesis. Gargini et al. showed 
that tau expression levels vary in different cancer types and 
high tau expression levels correlate with increased patient 
survival [82]. Another study found that MAPT knockdown 
enhanced cell growth and invasion and suggested that tau 
may be a tumour-suppressive protein in clear cell renal cell 
carcinoma [95]. The finding that MAPT mutations increase 
the risk of developing cancer suggests that tau mutations 
may result in loss of a tumour-suppressive function [223]. 
On the other hand, increased MAPT expression correlates 
with poor prognosis and taxane (a microtubule-stabilising 
drug) resistance in gastric cancer [180]. It appears that tau 
may have different effects depending on the cancer type 
being studied, highlighting the heterogeneous nature of can-
cer and the need for further research. As with Aβ, any poten-
tial for increased risk of cancer must be carefully assessed 
when designing tau-targeting therapeutics for AD.
Glucose metabolism
Dysregulation of insulin signalling in AD
Diabetes is a well-established risk factor for developing AD 
[152]. Insulin receptors are densely expressed in the hip-
pocampus, frontal cortex, and entorhinal cortex [49], with 
insulin playing key roles in a number of crucial CNS pro-
cesses such as synaptogenesis, synaptic remodelling [46], 
and regulation of memory [175]. The link between impaired 
insulin signalling and cognitive decline has been demon-
strated in humans and animal models [25, 49]. Indeed, 
impaired brain glucose metabolism is an early characteristic 
of AD, with one study reporting that up to 81% of individu-
als with AD had either type 2 diabetes or impaired fasting 
glucose, an indicator of prediabetes [119]. Whilst direct 
connections between glucose metabolism, tau, and Aβ have 
been made, it is important to highlight that the association 
between AD and diabetes could be, at least in part, due to 
diabetes-related blood vessel damage given the strong epi-
demiological links between many vascular risk factors and 
AD [152, 176].
Tau regulates normal glucose metabolism
Marciniak et al. reported that MAPT−/− mice exhibit insulin 
resistance in the hippocampus, suggesting that tau plays a 
normal role in the cellular response to insulin, a function that 
may be lost in AD [170]. The authors propose a mechanism, 
whereby tau normally interacts with PTEN, a phosphatase 
that inhibits insulin signalling, reducing its activity [170]. 
Tau is expressed in the pancreas [296], and MAPT−/− mice 
have been shown to develop pancreatic β cell dysfunction 
and glucose intolerance [279]. A recent imaging study in 
humans found that Aβ affected tau-glucose metabolism asso-
ciations [2]. This study reported that during normal ageing, 
small increases in tau are associated with increased glucose 
metabolism, but large accumulations of hyperphosphoryl-
ated tau associated with Aβ deposition correlated instead 
with hypometabolism, suggestive of a hormetic function 
for tau (Fig. 4), or Aβ-mediated dysregulation of normal 
tau function [2]. Interestingly, data from genome-wide 
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association studies have shown that the MAPT H1 haplotype 
is associated with increased glucose intolerance in humans 
[170]. Taken together, tau likely plays a role in the regula-
tion of homeostatic glucose metabolism. How this changes 
during disease, for example by loss of function caused by 
Aβ accumulation, or the potential effects of tau-targeting 
therapies on insulin signalling, requires further exploration.
Aβ‑processing enzymes regulate insulin signalling
Whilst Aβ has been proposed to dysregulate insulin sig-
nalling [25], there is mounting evidence that its cleavage 
enzyme, BACE1, which is strongly expressed in the pan-
creas [298], plays crucial physiological roles in glucose 
homeostasis. Indeed, BACE1−/− mice show impaired insu-
lin expression in the pancreas [104] and siRNA-mediated 
BACE1 knockdown significantly reduces insulin mRNA and 
protein in insulinoma cells [104]. However, another study 
reports that BACE1−/− mice have enhanced insulin sensi-
tivity [177]. Notably, hyperglycaemia increases BACE1-
mediated production of Aβ [142], indicative of a potentially 
vicious cycle between amyloid and glucose dysregulation. 
This also highlights the likely contribution of diseases such 
as diabetes mellitus to AD development and emphasises the 
potential of nutritional intervention strategies as a means of 
treating and preventing AD.
Conclusion
From molecular interactions with DNA to influencing 
complex behaviour, the physiological roles of tau (Fig. 5) 
and Aβ (Fig. 6) are multifaceted, dynamic, and at times, 
contradictory. This review emphasises the complexity of 
untangling physiology from pathology, as well as the wide-
reaching implications, for both the brain and body, that can 
be induced by subtle protein alterations. Whilst the range 
of functions which we discuss are diverse, common themes 
emerge:
• The functions of tau and Aβ are influenced by their loca-
tion. Shifts within the cell, expression in different cells 
or locations within the body, can alter the roles that these 
proteins play, whether they are beneficial or harmful, and 
how therapeutic treatments will influence function.
• Different isoforms, aggregation status, and post-transla-
tional modifications can dramatically alter the function 
of tau and Aβ.
• The concentrations of tau and Aβ are crucial for regu-
lating physiological versus pathological function. This 
“hormetic nature”, where too much or too little protein 
causes functional deficits, raises the likelihood of a “ther-
apeutic sweet spot” where the physiologically optimal 
Fig. 5  A schematic representation of the suggested physiological roles of tau in the brain and body. Created with https ://biore nder.com/
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concentrations lie, outside of which may result in damage 
(Fig. 4).
• AD is likely a combination of both gain- and loss-of-
function phenotypes. Physiological responses can 
become hijacked to become toxic, detrimental functions 
can appear, or normal functions can be lost during dis-
ease-related changes.
• Contradictory findings are common in the literature. The 
potential for developmental compensation in constitutive 
knockouts, as well as experimental differences in factors 
such as age, sex, and environment, will all impact out-
come. Future studies testing multiple timepoints, acute 
versus constitutive knockdown, different genetic back-
grounds, mixed-sex cohorts, and increasing comparisons 
between animal and human tissue will greatly clarify 
genuine phenotypes from experimental artefacts.
With the above in mind, a meticulous approach to therapeu-
tic development is crucial. Therapies must balance potentially 
detrimental effects of targeting tau (Table 1) and Aβ (Table 2) 
with the benefits of disrupting pathology. Targeting treatments 
early in the disease cascade, considering the individual’s medi-
cal history (such as previous injury and comorbidities), engag-
ing with modifiable lifestyle risk factors and the use of com-
binatorial therapies will likely be important to obtain the best 
outcome for individuals. By understanding the functions of tau 
and Aβ in health, we can gain greater insight into their contri-
bution to disease. Such research will be vital for the develop-
ment of safe and effective therapeutic strategies.
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